These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 21414119

  • 1. Risk factors for late-onset cytomegalovirus disease in donor seropositive/recipient seronegative kidney transplant recipients who receive antiviral prophylaxis.
    Boudreault AA, Xie H, Rakita RM, Scott JD, Davis CL, Boeckh M, Limaye AP.
    Transpl Infect Dis; 2011 Jun; 13(3):244-9. PubMed ID: 21414119
    [Abstract] [Full Text] [Related]

  • 2. Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation.
    Arthurs SK, Eid AJ, Pedersen RA, Kremers WK, Cosio FG, Patel R, Razonable RR.
    Clin Infect Dis; 2008 Mar 15; 46(6):840-6. PubMed ID: 18260785
    [Abstract] [Full Text] [Related]

  • 3. Diagnostic utility of monitoring cytomegalovirus-specific immunity by QuantiFERON-cytomegalovirus assay in kidney transplant recipients.
    Deborska-Materkowska D, Perkowska-Ptasinska A, Sadowska A, Gozdowska J, Ciszek M, Serwanska-Swietek M, Domagala P, Miszewska-Szyszkowska D, Sitarek E, Jozwik A, Kwiatkowski A, Durlik M.
    BMC Infect Dis; 2018 Apr 16; 18(1):179. PubMed ID: 29661141
    [Abstract] [Full Text] [Related]

  • 4. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T, Lai WK, Mutimer D.
    Transpl Infect Dis; 2005 Jun 16; 7(2):57-62. PubMed ID: 16150091
    [Abstract] [Full Text] [Related]

  • 5. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients.
    Jamal AJ, Husain S, Li Y, Famure O, Kim SJ.
    Transplantation; 2014 Mar 15; 97(5):569-75. PubMed ID: 24398852
    [Abstract] [Full Text] [Related]

  • 6. Cytomegalovirus serostatus pairing and deceased donor kidney transplant outcomes in adult recipients with antiviral prophylaxis.
    Kuo HT, Ye X, Sampaio MS, Reddy P, Bunnapradist S.
    Transplantation; 2010 Nov 27; 90(10):1091-8. PubMed ID: 20885340
    [Abstract] [Full Text] [Related]

  • 7. Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
    Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
    Transplantation; 2011 Jan 27; 91(2):251-5. PubMed ID: 21099744
    [Abstract] [Full Text] [Related]

  • 8. Incidence and clinical features of ganciclovir-resistant cytomegalovirus disease in heart transplant recipients.
    Li F, Kenyon KW, Kirby KA, Fishbein DP, Boeckh M, Limaye AP.
    Clin Infect Dis; 2007 Aug 15; 45(4):439-47. PubMed ID: 17638191
    [Abstract] [Full Text] [Related]

  • 9. Extended Low-Dose Valganciclovir Is Effective Prophylaxis Against Cytomegalovirus in High-Risk Kidney Transplant Recipients With Near-Complete Eradication of Late-Onset Disease.
    Fayek SA, Beshears E, Lieber R, Alvey N, Sauer A, Poirier J, Hollinger EF, Olaitan OK, Jensik S, Geyston J, Brokhof MM, Hodowanec AC, Hertl M, Simon DM.
    Transplant Proc; 2016 Aug 15; 48(6):2056-2064.e1. PubMed ID: 27569944
    [Abstract] [Full Text] [Related]

  • 10. Choice of induction regimens on the risk of cytomegalovirus infection in donor-positive and recipient-negative kidney transplant recipients.
    Luan FL, Samaniego M, Kommareddi M, Park JM, Ojo AO.
    Transpl Infect Dis; 2010 Dec 15; 12(6):473-9. PubMed ID: 20576019
    [Abstract] [Full Text] [Related]

  • 11. Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir.
    Razonable RR, Rivero A, Rodriguez A, Wilson J, Daniels J, Jenkins G, Larson T, Hellinger WC, Spivey JR, Paya CV.
    J Infect Dis; 2001 Dec 01; 184(11):1461-4. PubMed ID: 11709790
    [Abstract] [Full Text] [Related]

  • 12. Effect of Preemptive Therapy vs Antiviral Prophylaxis on Cytomegalovirus Disease in Seronegative Liver Transplant Recipients With Seropositive Donors: A Randomized Clinical Trial.
    Singh N, Winston DJ, Razonable RR, Lyon GM, Silveira FP, Wagener MM, Stevens-Ayers T, Edmison B, Boeckh M, Limaye AP.
    JAMA; 2020 Apr 14; 323(14):1378-1387. PubMed ID: 32286644
    [Abstract] [Full Text] [Related]

  • 13. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F, Alberú J, Soto-Ramírez LE, González-Aguirre H, Muñoz Trejo T, Mancilla E, Díliz H, Correa-Rotter R, Sierra-Madero J.
    Rev Invest Clin; 2002 Apr 14; 54(3):198-203. PubMed ID: 12183888
    [Abstract] [Full Text] [Related]

  • 14. Preemptive therapy is not adequate for prevention of cytomegalovirus disease in pancreas-kidney transplant recipients.
    López-Medrano F, Rueda B, Lizasoain M, Juan RS, Folgueira D, Andrés A, Morales JM, Jiménez C, Meneu JC, Aguado JM.
    Transpl Infect Dis; 2009 Oct 14; 11(5):400-4. PubMed ID: 19570139
    [Abstract] [Full Text] [Related]

  • 15. Late-onset cytomegalovirus disease in liver transplant recipients despite antiviral prophylaxis.
    Limaye AP, Bakthavatsalam R, Kim HW, Kuhr CS, Halldorson JB, Healey PJ, Boeckh M.
    Transplantation; 2004 Nov 15; 78(9):1390-6. PubMed ID: 15548980
    [Abstract] [Full Text] [Related]

  • 16. Late cytomegalovirus infection after oral ganciclovir prophylaxis in renal transplant recipients.
    Murray BM, Subramaniam S.
    Transpl Infect Dis; 2004 Mar 15; 6(1):3-9. PubMed ID: 15225220
    [Abstract] [Full Text] [Related]

  • 17. Incidence of Cytomegalovirus DNAemia in Pediatric Kidney Transplant Recipients After Cessation of Antiviral Prophylaxis.
    Chaiyapak T, Borges K, Williams A, Banh T, Vasilevska-Ristovska J, Allen U, Parekh RS, Hébert D.
    Transplantation; 2018 Aug 15; 102(8):1391-1396. PubMed ID: 29377877
    [Abstract] [Full Text] [Related]

  • 18. Cytomegalovirus prevention strategies in seropositive kidney transplant recipients: an insight into current clinical practice.
    Fernández-Ruiz M, Arias M, Campistol JM, Navarro D, Gómez-Huertas E, Gómez-Márquez G, Díaz JM, Hernández D, Bernal-Blanco G, Cofan F, Jimeno L, Franco-Esteve A, González E, Moreso FJ, Gómez-Alamillo C, Mendiluce A, Luna-Huerta E, Aguado JM, OPERA Study Group.
    Transpl Int; 2015 Sep 15; 28(9):1042-54. PubMed ID: 25864986
    [Abstract] [Full Text] [Related]

  • 19. Cytomegalovirus prophylaxis in seropositive renal transplant recipients receiving thymoglobulin induction therapy: Outcome and risk factors for late CMV disease.
    Reusing JO, Feitosa EB, Agena F, Pierrotti LC, Azevedo LSF, Kotton CN, David-Neto E.
    Transpl Infect Dis; 2018 Oct 15; 20(5):e12929. PubMed ID: 29809309
    [Abstract] [Full Text] [Related]

  • 20. Comparing cytomegalovirus prophylaxis in renal transplantation: single center experience.
    Varga M, Remport A, Hídvégi M, Péter A, Kóbori L, Telkes G, Fazakas J, Gerlei Z, Sárváry E, Sulyok B, Járay J.
    Transpl Infect Dis; 2005 Jun 15; 7(2):63-7. PubMed ID: 16150092
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.